SU 9803
Alternative Names: SU-9803Latest Information Update: 03 Mar 2008
Price :
$50 *
At a glance
- Originator SUGEN; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics
- Mechanism of Action Fibroblast growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn
- 28 May 1999 Preclinical development for Glioma in USA (Unknown route)